Amgen Announces Webcast to Discuss Results of Denosumab Phase 3 Head-to-Head Study Versus Alendronate at the Upcoming European Symposium on Calcified Tissues Conference

Update: Prolia (denosumab) Now FDA Approved - June 1, 2010
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 27, 2008 - Amgen (NASDAQ:AMGN) today announced that it will hold a conference call on Wednesday, May 28, 2008, beginning at 8 a.m. Eastern Time to discuss the results of the denosumab Phase 3 head-to-head study versus alendronate (the "141" study) at the upcoming European Symposium on Calcified Tissues (ECTS) Conference in Barcelona, Spain. Speakers will include the principal study investigator, Jacques P. Brown, M.D., Head, Division of Rheumatology, Le Centre hospitalier universitaire de Quebec, and Catherine Stehman-Breen, M.D., Amgen's vice president, Global Development - Bone Therapeutic Area.

Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. The conference call, including the question and answer session, is expected to last approximately one hour.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's Web site, www.amgen.com, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay 72 hours after the event.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

Contact

Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Arvind Sood, 805-447-1060 (investors)

Posted: May 2008

View comments

Hide
(web2)